

82. The pharmaceutical composition of claim **66**, wherein the composition is formulated for intra-articular injection within a joint of a subject.

83. A pharmaceutical composition for the treatment or prevention of a joint disease or condition, comprising:

a therapeutically effective amount of one or more nucleic acids encoding a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene-editing system, the system comprising:

- (i) a CRISPR Associated Protein 9 (Cas9) protein; and
- (ii) at least one guide RNA targeting an IL-1 β gene, wherein:

the at least one guide RNA comprises a crRNA sequence that is complementary to a target sequence in exon 4 of the IL-1 β gene, and

the target sequence is adjacent to a protospacer adjacent motif (PAM) sequence for the Cas9 protein.

84. The pharmaceutical composition of claim **83**, wherein the composition comprises one or more viral vectors collectively comprising the one or more nucleic acids.

85. The pharmaceutical composition of claim **84**, wherein the one or more viral vectors comprise a recombinant virus selected from a retrovirus, an adenovirus, an adeno-associated virus, a lentivirus, and a herpes simplex virus-1

86. The pharmaceutical composition of claim **84**, wherein the one or more viral vectors comprise a recombinant adeno-associated virus (AAV).

87. The pharmaceutical composition of claim **86**, wherein the recombinant AAV is of serotype 5 (AAV5).

88. The pharmaceutical composition of claim **86**, wherein the recombinant AAV is of serotype 6 (AAV6).

89. The pharmaceutical composition of claim **84**, wherein the one or more viral vectors comprise:

a first viral vector comprising a first nucleic acid, in the one or more nucleic acids, encoding the Cas9 protein; and

a second viral vector comprising a second nucleic acid, in the one or more nucleic acids, encoding the at least one guide RNA.

90. The pharmaceutical composition of claim **84**, wherein the one or more viral vectors comprise a viral vector comprising a single nucleic acid, wherein the single nucleic acid encodes the Cas9 protein and the at least one guide RNA.

91. The pharmaceutical composition of claim **83**, wherein the composition comprises one or more liposomes collectively comprising the one or more nucleic acids.

92. The pharmaceutical composition of claim **83**, wherein the one or more nucleic acids are present in a naked state.

93. The pharmaceutical composition of claim **83**, wherein the Cas9 protein is an *S. pyogenes* Cas9 polypeptide.

94. The pharmaceutical composition of claim **83**, wherein the Cas9 protein is an *S. aureus* Cas9 polypeptide.

95. The pharmaceutical composition of claim **83**, wherein the IL-1 β gene is a human IL-1 β gene.

96. The pharmaceutical composition of claim **83**, wherein the IL-1 β gene is a canine IL-1 β gene.

97. The pharmaceutical composition of claim **83**, wherein the IL-1 β gene is an equine IL-1 β gene.

98. The pharmaceutical composition of claim **83**, wherein the composition is formulated for parenteral administration.

99. The pharmaceutical composition of claim **83**, wherein the composition is formulated for intra-articular injection within a joint of a subject.

* * * * *